EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Fragility of randomised controlled trials for systemic lupus erythematosus and lupus nephritis therapies

Gabriel Figueroa-Parra iD, Michael S Putman, Cynthia S Crowson, Alí Duarte-García iD

Lupus Science & Medicine · 2024

DOI: 10.1136/lupus-2023-001068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lupus Science & Medicine, 2024. Verfasst von Gabriel Figueroa-Parra und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Lupus Nephritis, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We aimed to evaluate the robustness of phase III randomised controlled trials (RCTs) for SLE and lupus nephritis (LN) using the fragility index (FI), the reverse FI (RFI) and the fragility quotient (FQ).

Methods

We searched for phase III RCTs that included patients with active SLE or LN. Data on primary endpoints, total participants and the number of events for each arm were obtained. We calculated the FI score for RCTs with statistically significant results (number of patients required to change from event to non-event to make the study lose statistical significance), the RFI for RCTs without statistically significant results (number of patients required to change from non-event to event to make study gain statistical significance) and the FQ score for both (FI or RFI score divided by the sample size).

Results

We evaluated 20 RCTs (16 SLE, four LN). The mean FI/RFI score was 13.6 (SD 6.6). There were nine RCTs with statistically significant results (seven SLE, two LN), and the mean FI score was 10.2 (SD 6.2). The lowest FI was for the ILLUMINATE-2 trial (FI=2), and the highest FI was for the BLISS-52 trial (FI=17). Twelve studies had non-statistically significant results (10 SLE, two LN) with a mean RFI score of 15.6 (SD 6.1). The lowest RFI was for the ILLUMINATE-1 trial (RFI=4), and the highest RFI was for the TULIP-1 trial (RFI=27). The lowest FQ scores were found in the ILLUMINATE trials and the highest in the Rituximab trials (EXPLORER and LUNAR), meaning that the last ones were the most robust results after accounting for sample size.

Conclusions

The evidence of therapies for patients with SLE and LN is derived mostly from fragile RCTs. Clinicians and trialists must be aware of the fragility of these RCTs for clinical decision-making and designing trials for novel therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicLupus NephritisRandomized Controlled Trials as TopicHumansClinical Decision-MakingRituximab

Stichwörter der Autor:innen

Clinical TrialLupus NephritisSystemic Lupus ErythematosusTherapeutics

Substanzen

Rituximab

Autor:innen und Institutionen

  • Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA duarte.ali@mayo.edu.
  • Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Gabriel Figueroa-Parra, Alí Duarte-García

Förderung

  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences

Zitieren

APA

Figueroa-Parra, G., Putman, M. S., Crowson, C. S., & Duarte-García, A. (2024). Fragility of randomised controlled trials for systemic lupus erythematosus and lupus nephritis therapies. Lupus Science & Medicine. https://doi.org/10.1136/lupus-2023-001068

Vancouver

Figueroa-Parra G, Putman MS, Crowson CS, Duarte-García A. Fragility of randomised controlled trials for systemic lupus erythematosus and lupus nephritis therapies. Lupus Science & Medicine. 2024. doi:10.1136/lupus-2023-001068

BibTeX
@article{FigueroaParra2024,
  author = {Figueroa-Parra, Gabriel and Putman, Michael S and Crowson, Cynthia S and Duarte-García, Alí},
  title = {Fragility of randomised controlled trials for systemic lupus erythematosus and lupus nephritis therapies},
  journal = {Lupus Science & Medicine},
  year = {2024},
  doi = {10.1136/lupus-2023-001068}
}
Kostenlos starten →